Chiral diarylmethanols are important building blocks for many antihistamine compounds or therapeutic agents such as (R)-orphenadrine, (S)-neobenodine, (S)-carbinoxamine, and bepotastine.catalytic methods for the syntheses of chiral diarylmethanols has thus gained significant interest [5] In this presentation, we will discuss our new progress in application of a novel ruthenium catalyst on the basis of a chiral monophosphorus ligand for the asymmetric addition of arylboronic acids to aryl aldehydes, providing a series of chiral diarylmethanols in excellent yields and enantioselectivities (up to 92％ ee).Preliminary study has shown this process is catalyzed by a Ru complex with a single monophosphorus ligand.